It’s evidence of another global jurisdiction who sees material benefit in Wheezo as a core part of a platform to manage asthma along with a smart inhaler…nothing fluffy about that at all actually very material in what it means to the process of the company’s technology adoption. Focus is still on the US market as the main priority.
